Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P04637 (p53)
 77,613 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Human colon cancer is a multistage disease which has been shown to have a number of well-defined histological and genetic events. This knowledge has identified a series of stages in the development of colon cancer in which dietary components and chemicals may play either a beneficial or detrimental role. Azoxymethane-induced colon cancer in the rat represents a way of investigating such effects on the temporal development of the disease. To assess the stages involved in the long-term development of colon cancer in this animal model, Sprague-Dawley rats were treated with either one or two (given 24 hours apart) doses of azoxymethane (15 mg/kg). These low doses were chosen in an attempt to mimic the slow development of the human disease. At varying time intervals (5-84 weeks) after treatment, animals were killed and their colons were examined for lesions. Evidence was found in the distal region of the colon of a progression from early alterations (aberrant crypt foci) to microadenomas and polyps. This progression occurs in the region where carcinomas were found. The best correlation with tumorigenicity was the multiplicity of the crypts in each focus rather than simply the number of aberrant crypt foci. The aberrant crypts were microdissected from the colon and DNA was prepared. The following genes were screened for mutation using polymerase chain reaction with single-strand conformation polymorphism, oligonucleotide hybridisation, restriction site changes and sequencing: Ki-ras (exons 1 and 2), p53 (exons 5, 6, and 7 which correspond to exons 5-8 in humans), and APC (exon 15 corresponding to the mutation cluster region in humans). Extensive studies of the aberrant crypt foci formed revealed no mutations in these lesions. These results suggest that the aberrant crypt focus may be a useful short-term preneoplastic marker. However, it is clear from this and other studies that the genetic progression in the rat may vary according to the treatment regimen used and differs from that found in human. Key genes in the development of colon cancer in the rat remain to be elucidated.
Teratog Carcinog Mutagen 1998
PMID:Long-term analysis of colonic aberrant crypt formation after treatment of Sprague-Dawley rats with azoxymethane. 980 74

Individual variability of scoring foci positive for transformation presents a difficult problem in assessing the transformation assay. In this study, an attempt was made to identify five morphologically distinct types of transformed foci based on size (2-3, 3-4, and > or = 4 mm in diameter), invasiveness (smooth vs. invading margins), and other properties (piling vs. spread) induced by 3-methylcholanthrene in Balb/c-3T3 cells. The transformed focal cells were used in in vitro studies including anchorage-independent analysis, focal reconstruction, gene transfection using NIH-3T3 host cells, and Southern blotting to assess amplification of five proto-oncogenes (K-ras, H-ras, c-fos, c-jun, c-myc) and a tumor suppressor (p53) gene. Results showed that 1) there was a significant increase in anchorage-independent growth of all five types of foci ranging from 7-12%; 2) all five morphological types of transformed foci showed 8-15% focal reconstruction; 3) DNA from all five types of transformed foci induced transformation in NIH-3T3 cells at a level significantly above the control DNA; 4) gene amplification studies indicated amplification in both K-ras and H-ras proto-oncogenes; however, c-fos, c-jun, and c-myc did not show DNA amplification. The tumor suppressor gene (p53) was activated and the increase was up to 3-fold over the normal Balb/c-3T3 DNA. These findings are consistent with our hypothesis that all five morphologically different foci have preneoplastic potential and that any foci of size > or = 2 mm regardless of invasiveness and piling should be scored as positive during the transformation assay.
Environ Mol Mutagen 1998
PMID:Preneoplastic potential of morphologically distinct transformed foci induced by 3-methylcholanthrene. 988 12

Both K-ras and p53 gene mutations are found commonly in pancreatic tumors. Analysis of the mutational patterns may provide insight into disease etiology. To further describe the mutational patterns of pancreatic cancer and to assess the evidence to date, we performed a pooled analysis of the published data on genetic mutations associated with pancreatic ductal adenocarcinoma. We included data from studies that evaluated point mutations in the two genes most studied in pancreatic cancer, K-ras and p53. A majority of the 204 tumors had mutations in at least one gene, with 29% having both K-ras and p53 mutations, 39% with K-ras mutation alone, and 16% having p53 mutation alone. Sixteen percent of tumors lacked mutation in either gene. K-ras mutations were present in high frequencies in all tumor grades (>69%). A statistically significant trend was observed for p53 mutation with higher tumor grade (P = 0.04). For K-ras, G2 and G3 grades, combined, had notably higher prevalences of mutation than G1 (P = 0.004). CGT mutations in K-ras codon 12 were marginally associated with lower tumor grade (P for trend = 0.09), and these tumors were somewhat less likely to have a p53 mutation than tumors with other K-ras mutations (P = 0.06). In the 59 K-ras+/p53+ tumors, 64% had the same type of mutation (transition or transversion) in both genes, suggesting a common mechanism. The mutational pattern of p53 in pancreatic cancer is similar to bladder cancer, another smoking-related cancer, but not to lung cancer. Analyses of molecular data, such as that performed here, present new avenues for epidemiologists in the study of the etiology of specific cancers.
Environ Mol Mutagen 1999
PMID:Patterns of genetic alterations in pancreatic cancer: a pooled analysis. 1021 65

The p53 gene is a tumour suppressor gene which has a fundamental role in cell cycle control and division, and in mammals certain genotoxic agents induce specific mutations in p53, leading to tumourigenesis. Fish have been investigated as models for studying carcinogens, but as yet very little data exists that links exposure to specific chemicals with the aetiology of tumours found in wild populations. In this study, p53 was sequenced from five species of fish with a view to the possible use of mutations in the highly conserved domains of p53 to identify genotoxins in the aquatic environment. A 0.8 kb fragment of the cDNA encompassing the conserved DNA-binding domain of p53 was sequenced in three Oncorhynchus salmonid fish: coho (O. kisutch), chum (O. keta), and chinook (O. tshawytscha) and full-length p53 cDNAs were sequenced in the puffer fish (Tetraodon miurus) and the barbel (Barbus barbus). The full-length puffer fish and barbel p53 cDNAs were 1834 bp and 1790 bp in length, encoding a 367 aa protein and a 369 aa protein, respectively. The deduced aa sequences of the p53 cDNA in the Oncorhynchus salmon shared a 100% identity in the five conserved regions (I-V). Comparisons of the deduced aa sequences for puffer fish and barbel p53 with other fish p53s revealed a high homology within the conserved DNA binding domain (68-86% for puffer fish and between 66-88% for barbel). "Conserved" domain I was not highly conserved in fish, as it is in mammals, and, therefore, conserved domains II-V are most likely to provide the valuable sequences in fish p53 for use in mutational studies to fingerprint genotoxins in the aquatic environment.
Environ Mol Mutagen 1999
PMID:Fish p53 as a possible biomarker for genotoxins in the aquatic environment. 1033 19

This study was aimed at characterizing the temporal patterns of cell responses and p53 protein expression in the limbs, head, and liver of embryos responding to cyclophosphamide (CP)-induced teratogenic insult. ICR murine embryos were examined 24, 48, or 72 h after injection of 40 mg/kg CP on day 12 of pregnancy. The cellular events and temporal pattern of p53 protein expression were determined by FACS analysis and by TUNEL (apoptosis) in the head, limbs, and liver of the embryos. All tested organs showed apoptosis and a significantly decreased proportion of live cells after 24 h. Subsequent events were organ-dependent. In the liver, there were no dysmorphic events at any time and excessive cell death had been almost compensated for by 48 h. Compensation was preceded by G(1) arrest and accompanied by an increased level of p53 protein in surviving cells. Excessive cell death in the head and the limbs resulted in structural anomalies. In the head, there was an increased level of p53 protein and G(1) arrest after 24 h and the number of live cells at 48 h was equal to that seen in earlier samples, despite apoptosis. In the limbs, however, only isolated viable cells were seen by 48 h, but there was no increased level of p53 protein or G(1) arrest. Results of this study suggest that the differential sensitivity of tested organ systems to CP may be associated with differences in cellular events following CP-initiated cell death. They also suggest that the input of p53 in determining the response of these organ systems to CP-induced teratogenic insult may be different. Teratogenesis Carcinog. Mutagen. 19:353-367, 1999.
Teratog Carcinog Mutagen 1999
PMID:Cellular events and the pattern of p53 protein expression following cyclophosphamide-initiated cell death in various organs of developing embryo. 1049 52

XPA-deficient mice have a complete deficiency in nucleotide excision repair, and as such they display a cancer predisposition after exposure to several carcinogens. Besides being sensitive to genotoxic agents applied to the skin, they are also susceptible to human carcinogens given orally, like benzo[a]pyrene (B[a]P). To study the role of the tumor suppressor gene p53 in DNA repair, gene mutation, and tumor induction, we crossed XPA-deficient mice with p53 knockout mice and lacZ (pUR288) gene marker mice. When treated orally (by gavage) with B[a]P, the XPA(-/-)/p53(+/-) double transgenic mice developed tumors much earlier and with higher frequency compared to their single transgenic counterparts. The major tumor type found in all genotypes was generalized lymphoma mainly residing in the spleen; several sarcomas were observed in p53(+/-) and XPA(-/-)/p53(+/-) mice. Next, we determined lacZ mutation frequencies in several (non)target tissues. It appeared that in the spleen (the major tumor target tissue) of XPA(-/-) and XPA(-/-)/p53(+/-) mice the lacZ mutation frequency was significantly elevated (80-100 x 10(-5)), and was two times higher as found in spleens of B[a]P-treated WT and p53(+/-) mice (P = 0.003). In nontumor target tissues like liver and lung, we found a moderate increase in the lacZ gene mutation frequency (30-40 x 10(-5)), which was independent of the genotype. The results obtained with the DNA-repair deficient XPA mice indicate that a significantly increased lacZ mutation frequency in a particular organ/tissue is an early marker for tumor development at later stages at the same site. However, the synergistic effect of a XPA(-/-)- and a p53(+/-)-deficiency in tumor development is not reflected by an absolute increase in the lacZ mutation frequency in the major tumor target tissue of XPA(-/-)/p53(+/-) or p53(+/-) mice compared to that of XPA(-/-) and WT mice, respectively.
Environ Mol Mutagen 1999
PMID:Effect of heterozygous loss of p53 on benzo[a]pyrene-induced mutations and tumors in DNA repair-deficient XPA mice. 1052 36

Comparison of the mutation patterns of p53 in human tumors with those of selectable genes in model systems is a powerful approach to identify potential etiological factors for specific tumor types. Recently, we validated use of a yeast assay to permit direct determination of the mutation spectrum induced in human p53 by carcinogens that would reduce uncertainties inherent in comparing spectra induced in different target genes. Here, we describe modifications in the assay designed to facilitate screening for mutants and to permit intracellular exposure of the gene instead of in vitro treatment. This was accomplished by introducing growth-based selection for transactivation-deficient p53 mutants into yeast already possessing red/white colony color selection. This improved model system was able to detect cells harboring p53 mutations among cells with wild-type p53 at a frequency of 10(-4) or less. Additionally, UV light was used to verify that the majority of mutagenized cells with the appropriate phenotype on selective medium contained mutations in p53, not elsewhere in the genome. Sequence analysis of UV-induced mutations revealed that the nature of the mutations was similar to those obtained in previous studies of this mutagen. This system will prove useful in the determination of the ability of environmental agents to mutate the human p53 gene, and thus may contribute to hazard identification.
Environ Mol Mutagen 2000
PMID:UV-induced mutagenesis of human p53: analysis using a double-selection method in yeast. 1069 25

We report here the successful application of the restriction site mutation (RSM) assay in detecting 2-acetylaminofluorene (2-AAF)-induced mouse liver mutations. A total of seven 2-AAF-induced liver mutations were detected out of a total of 304 analyses performed on 2-AAF-treated liver tissue. No mutations were detected in the 190 RSM analyses performed on untreated liver tissue. The 2-AAF-induced point mutations comprised 60% GC-->TA transversions, 30% GC-->AT transitions, 10% GC-->CG transversions, and 1 insertional event was also detected. All seven mutations were detected in intron 6 of the mouse p53 gene, with no mutations detectable in exons 4 or 5, supporting our previous data on the greater mutability of intron regions. In addition to the RSM analysis, we also report the application of the in vivo bone marrow micronucleus assay in detecting the clastogenicity of 2-AAF. We detected a small, but statistically significant, increase in the number of micronuclei induced by 2-AAF, but only after 2,000 cells were scored. This also confirms previous data showing that 2-AAF is a weak clastogen. Finally, we attempted to compare the sensitivity of the two assays to 2-AAF-induced genotoxicity, as had been previously undertaken with ENU. Both assays detected genotoxicity in their respective tissues; however, different endpoints were analysed. The RSM assay appears to be more adaptable than the micronucleus assay, due to its tissue and organism independence and has the potential to provide more molecular information on genotoxicity. Teratogenesis Carcinog. Mutagen. 20:107-117, 2000.
Teratog Carcinog Mutagen 2000
PMID:Restriction site mutation (RSM) analysis of 2-acetylaminofluorene (2-AAF)-induced mouse liver mutations and comparison with the measurement of in vivo micronucleus induction in the bone marrows of (2-AAF)-treated mice. 1082 Apr 21

Cell transformation is one of the most common assays used to study morphological changes in the multistep process of carcinogenesis. The present study was initiated to investigate the ability of crocidolite to induce cell transformation in BALB/c-3T3 cells and to analyze the relationship between p53 mutations and crocidolite-induced cell transformation, if any. Cell transformation was carried out according to standard procedures. Exponentially growing cells were exposed to different concentrations (0.2-20 microg/cm(2)) of crocidolite fibers for 72 h. Foci obtained from cell transformation were analyzed for their ability to grow in soft agar (anchorage-independence) and p53 alterations. The results of this study demonstrate that there was an increase in transformation frequency (TF) with an increase in concentration of crocidolite. Also, focal cells were able to grow on soft agar, indicating anchorage-independence. cDNA was prepared from RNA isolated from Type 3 foci and subjected to mutational analysis. Eleven exons of the p53 gene from eight transformed cell lines were analyzed for alterations using polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP). Alterations were found in seven of eight cell lines, two of them were in exons 4-6, and five in exons 9-11. The alterations were randomly scattered among the crocidolite dose groups. These results suggest that crocidolite induces mutations predominantly in exons 9-11 of the p53 gene in a nondose-dependent manner.
Teratog Carcinog Mutagen 2000
PMID:Crocidolite induces cell transformation and p53 gene mutation in BALB/c-3T3 cells. 1099 74

We report the results of a collaborative study aimed at developing reliable, direct assays for mutation in human cells. The project used common lymphoblastoid cell lines, both with and without mutagen treatment, as a shared resource to validate the development of new molecular methods for the detection of low-level mutations in the presence of a large excess of normal alleles. As the "gold standard, " hprt mutation frequencies were also measured on the same samples. The methods under development included i) the restriction site mutation (RSM) assay, in which mutations lead to the destruction of a restriction site; ii) minisatellite length-change mutation, in which mutations lead to alleles containing new numbers of tandem repeat units; iii) loss of heterozygosity for HLA epitopes, in which antibodies can be used to direct selection for mutant cells; iv) multiple fluorescence-based long linker arm nucleotides assay (mf-LLA) technology, for the detection of substitutional mutations; v) detection of alterations in the TP53 locus using a (CA) array as the target for the screening; and vi) PCR analysis of lymphocytes for the presence of the BCL2 t(14:18) translocation. The relative merits of these molecular methods are discussed, and a comparison made with more "traditional" methods.
Teratog Carcinog Mutagen 2000
PMID:Molecular methods for the detection of mutations. 1107 20


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>